
Pharmacally
Finerenone
Approvals, trial readouts, research and drug safety alerts, interpreted by pharmacists and checked against the primary source.
Latest in Finerenone
New Drug ApprovalNICE Recommends Finerenone for Chronic Heart Failure with Preserved or Mildly Reduced Ejection FractionNICE has issued final draft guidance recommending finerenone (Kerendia) for adults with symptomatic chronic heart failure and a left ventricular ejection fraction (LVEF) of 40% or greater.Fact-Checked
Clinical TrialsBayer’s Finerenone Delivers Positive Phase III Results in Non-Diabetic CKDThe pivotal FIND-CKD trial demonstrated that finerenone preserved kidney function and reduced cardiovascular-kidney complications in adults with non-diabetic CKD.Fact-Checked
Health TidingsEU Expands Kerendia Label: Bayer’s Finerenone Approved for Broader Heart Failure PopulationThe EU expands Kerendia’s label to heart failure with LVEF ≥40%, with Phase III data supporting significant reductions in cardiovascular death and heart failure events.Fact-Checked
Explore more
Health TidingsIndustry, pipeline and company news.
RegulatoryApprovals, policy and agency decisions.
ResearchPeer-reviewed studies and scientific breakthroughs.
Drug FinderLook up any drug: uses, dosing and safety.
From the HistoryLandmark moments in pharmaceutical history.
LatestEvery new story, as soon as it is published.